drugset / Trial / NCT04182581
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The study is an early, open, single-centered trial. The purpose of this study is to evaluate the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T therapy.
Timeline
- Start
- 2019-10-15
- Primary completion
- 2020-09
- Completion
- 2021-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA/CD19 Dual-Target CAR-T | Cell therapy | 50000 cells/kg | — |
| Subject | BCMA/CD19 Dual-Target CAR-T | Cell therapy | 300000 cells/kg | — |